| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nicotine | 21 | 2023 | 238 | 5.520 |
Why?
|
| Nicotinic Agonists | 6 | 2019 | 68 | 2.060 |
Why?
|
| Fatty Liver | 4 | 2021 | 56 | 1.510 |
Why?
|
| Cushing Syndrome | 2 | 2020 | 5 | 1.440 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2023 | 592 | 1.290 |
Why?
|
| Mice, Inbred C57BL | 19 | 2023 | 1530 | 1.140 |
Why?
|
| Proprotein Convertase 2 | 7 | 2013 | 16 | 1.140 |
Why?
|
| Morphine | 4 | 2013 | 80 | 1.000 |
Why?
|
| Mice | 30 | 2023 | 5668 | 0.960 |
Why?
|
| Hepatocytes | 5 | 2012 | 74 | 0.940 |
Why?
|
| Animals | 43 | 2023 | 14307 | 0.920 |
Why?
|
| Endoribonucleases | 1 | 2023 | 23 | 0.910 |
Why?
|
| Smoking | 6 | 2022 | 903 | 0.900 |
Why?
|
| Melatonin | 1 | 2023 | 78 | 0.890 |
Why?
|
| Analgesics, Opioid | 4 | 2013 | 176 | 0.880 |
Why?
|
| Corticosterone | 6 | 2019 | 73 | 0.880 |
Why?
|
| Receptors, Glucocorticoid | 3 | 2008 | 31 | 0.870 |
Why?
|
| Male | 43 | 2021 | 18870 | 0.870 |
Why?
|
| Depressive Disorder, Major | 1 | 2023 | 102 | 0.850 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2023 | 146 | 0.840 |
Why?
|
| Insulin Resistance | 6 | 2019 | 177 | 0.840 |
Why?
|
| Carbohydrate Dehydrogenases | 5 | 2019 | 14 | 0.830 |
Why?
|
| RNA-Binding Proteins | 1 | 2023 | 145 | 0.820 |
Why?
|
| Prediabetic State | 3 | 2012 | 51 | 0.810 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 32 | 0.780 |
Why?
|
| Adrenal Glands | 1 | 2020 | 17 | 0.780 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 7 | 2019 | 17 | 0.770 |
Why?
|
| Proprotein Convertase 1 | 6 | 2013 | 11 | 0.740 |
Why?
|
| Hypoglycemic Agents | 2 | 2015 | 152 | 0.730 |
Why?
|
| Hyperglycemia | 2 | 2015 | 53 | 0.720 |
Why?
|
| Insulin | 4 | 2016 | 224 | 0.710 |
Why?
|
| Mexican Americans | 1 | 2021 | 177 | 0.710 |
Why?
|
| Aerosols | 1 | 2019 | 48 | 0.700 |
Why?
|
| Life Style | 1 | 2021 | 288 | 0.700 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2020 | 88 | 0.700 |
Why?
|
| Stroke Volume | 1 | 2019 | 97 | 0.670 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 104 | 0.670 |
Why?
|
| Blood Glucose | 6 | 2019 | 333 | 0.660 |
Why?
|
| Dexamethasone | 1 | 2018 | 43 | 0.650 |
Why?
|
| Smoking Cessation | 3 | 2023 | 487 | 0.650 |
Why?
|
| Atherosclerosis | 1 | 2019 | 131 | 0.630 |
Why?
|
| Behavior, Animal | 2 | 2019 | 304 | 0.630 |
Why?
|
| Diet | 2 | 2021 | 747 | 0.610 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 2013 | 50 | 0.580 |
Why?
|
| Pituitary Neoplasms | 2 | 2008 | 5 | 0.580 |
Why?
|
| Hypopituitarism | 2 | 2008 | 2 | 0.570 |
Why?
|
| Humans | 29 | 2023 | 34853 | 0.560 |
Why?
|
| Human Growth Hormone | 2 | 2008 | 20 | 0.560 |
Why?
|
| Brain | 3 | 2013 | 1268 | 0.560 |
Why?
|
| Drug Monitoring | 1 | 2015 | 17 | 0.540 |
Why?
|
| Health Status Disparities | 1 | 2021 | 583 | 0.530 |
Why?
|
| Lipolysis | 4 | 2023 | 18 | 0.520 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 48 | 0.520 |
Why?
|
| Drug Resistance | 1 | 2015 | 93 | 0.510 |
Why?
|
| Mice, Obese | 6 | 2020 | 37 | 0.490 |
Why?
|
| Protein Precursors | 4 | 2006 | 59 | 0.490 |
Why?
|
| Pituitary Gland | 4 | 2020 | 59 | 0.490 |
Why?
|
| Endocrine System Diseases | 2 | 2012 | 12 | 0.480 |
Why?
|
| Pro-Opiomelanocortin | 1 | 2013 | 14 | 0.470 |
Why?
|
| Morphine Dependence | 1 | 2013 | 25 | 0.470 |
Why?
|
| Obesity | 4 | 2023 | 965 | 0.470 |
Why?
|
| Narcotics | 1 | 2013 | 28 | 0.470 |
Why?
|
| Oxidative Stress | 9 | 2020 | 874 | 0.470 |
Why?
|
| Body Weight | 6 | 2016 | 404 | 0.460 |
Why?
|
| Myocytes, Cardiac | 3 | 2020 | 165 | 0.450 |
Why?
|
| Adipose Tissue | 4 | 2019 | 167 | 0.440 |
Why?
|
| Thyrotropin-Releasing Hormone | 3 | 2006 | 11 | 0.430 |
Why?
|
| Receptors, Vasopressin | 1 | 2012 | 2 | 0.430 |
Why?
|
| Eating | 1 | 2013 | 152 | 0.430 |
Why?
|
| Glucocorticoids | 3 | 2019 | 80 | 0.420 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2012 | 25 | 0.420 |
Why?
|
| Body Composition | 2 | 2014 | 146 | 0.420 |
Why?
|
| Cholecalciferol | 1 | 2011 | 19 | 0.410 |
Why?
|
| Fasting | 1 | 2011 | 50 | 0.410 |
Why?
|
| Mice, Knockout | 10 | 2019 | 897 | 0.400 |
Why?
|
| Female | 19 | 2021 | 19873 | 0.400 |
Why?
|
| Hydrocortisone | 3 | 2020 | 72 | 0.400 |
Why?
|
| Cotinine | 3 | 2020 | 40 | 0.400 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2020 | 342 | 0.390 |
Why?
|
| Gene Expression Regulation | 5 | 2013 | 968 | 0.390 |
Why?
|
| Androgens | 3 | 2014 | 87 | 0.390 |
Why?
|
| Vitamin D | 1 | 2012 | 176 | 0.380 |
Why?
|
| Testosterone | 3 | 2014 | 181 | 0.370 |
Why?
|
| Endocrine System | 1 | 2009 | 12 | 0.370 |
Why?
|
| Opiate Alkaloids | 1 | 2009 | 8 | 0.370 |
Why?
|
| Feeding Behavior | 1 | 2013 | 418 | 0.350 |
Why?
|
| Middle Aged | 10 | 2020 | 9642 | 0.330 |
Why?
|
| Adult | 11 | 2023 | 11034 | 0.330 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 1300 | 0.330 |
Why?
|
| Pituitary Hormones, Anterior | 1 | 2008 | 2 | 0.330 |
Why?
|
| Parathyroid Neoplasms | 1 | 2007 | 1 | 0.320 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 66 | 0.310 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2007 | 14 | 0.310 |
Why?
|
| Hypothyroidism | 2 | 2006 | 18 | 0.310 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2014 | 160 | 0.300 |
Why?
|
| Animal Feed | 2 | 2020 | 42 | 0.300 |
Why?
|
| Adolescent | 4 | 2023 | 5035 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 984 | 0.300 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2006 | 5 | 0.300 |
Why?
|
| Proprotein Convertases | 1 | 2006 | 8 | 0.300 |
Why?
|
| Adenoma | 1 | 2008 | 89 | 0.290 |
Why?
|
| Pituitary-Adrenal System | 1 | 2006 | 36 | 0.290 |
Why?
|
| Carcinoma | 1 | 2007 | 94 | 0.290 |
Why?
|
| RNA, Messenger | 6 | 2013 | 1152 | 0.290 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2006 | 49 | 0.290 |
Why?
|
| Immune System | 2 | 2023 | 40 | 0.290 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2006 | 58 | 0.290 |
Why?
|
| Adiposity | 3 | 2019 | 145 | 0.290 |
Why?
|
| Sulfonamides | 1 | 2006 | 75 | 0.280 |
Why?
|
| Liver | 4 | 2013 | 447 | 0.280 |
Why?
|
| Young Adult | 3 | 2021 | 4012 | 0.280 |
Why?
|
| Triiodothyronine | 2 | 2005 | 30 | 0.280 |
Why?
|
| Apoptosis | 3 | 2020 | 1317 | 0.270 |
Why?
|
| Retrospective Studies | 3 | 2020 | 1961 | 0.270 |
Why?
|
| Drug Administration Schedule | 3 | 2015 | 145 | 0.260 |
Why?
|
| Hypogonadism | 3 | 2012 | 21 | 0.260 |
Why?
|
| Narcotic Antagonists | 3 | 2013 | 50 | 0.260 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2013 | 87 | 0.260 |
Why?
|
| Stress, Psychological | 2 | 2010 | 541 | 0.260 |
Why?
|
| Weight Gain | 2 | 2016 | 128 | 0.250 |
Why?
|
| Phenotype | 2 | 2023 | 650 | 0.250 |
Why?
|
| Reward | 3 | 2013 | 73 | 0.250 |
Why?
|
| Prolactinoma | 1 | 2004 | 1 | 0.250 |
Why?
|
| Ergolines | 1 | 2004 | 2 | 0.250 |
Why?
|
| Hyperprolactinemia | 1 | 2004 | 3 | 0.250 |
Why?
|
| Conditioning, Operant | 3 | 2013 | 72 | 0.250 |
Why?
|
| Central Nervous System Cysts | 1 | 2004 | 1 | 0.250 |
Why?
|
| Pituitary Diseases | 1 | 2004 | 2 | 0.250 |
Why?
|
| Pituitary Gland, Anterior | 1 | 2004 | 10 | 0.250 |
Why?
|
| Intracranial Aneurysm | 1 | 2004 | 9 | 0.250 |
Why?
|
| Carotid Arteries | 1 | 2004 | 29 | 0.240 |
Why?
|
| Tobacco Use Disorder | 2 | 2023 | 229 | 0.240 |
Why?
|
| Postmenopause | 2 | 2014 | 125 | 0.240 |
Why?
|
| Abdominal Fat | 2 | 2014 | 21 | 0.240 |
Why?
|
| Feedback | 1 | 2023 | 46 | 0.230 |
Why?
|
| AMP-Activated Protein Kinases | 4 | 2020 | 49 | 0.230 |
Why?
|
| Palmitates | 1 | 2023 | 13 | 0.230 |
Why?
|
| Endocrine Glands | 1 | 2003 | 3 | 0.230 |
Why?
|
| Rats | 8 | 2013 | 3261 | 0.230 |
Why?
|
| Hep G2 Cells | 1 | 2023 | 52 | 0.230 |
Why?
|
| Leptin | 2 | 2004 | 115 | 0.220 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 522 | 0.220 |
Why?
|
| Chagas Disease | 1 | 2004 | 96 | 0.220 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 484 | 0.220 |
Why?
|
| Fatty Acids | 1 | 2023 | 118 | 0.210 |
Why?
|
| beta-Endorphin | 3 | 2012 | 14 | 0.210 |
Why?
|
| Hospital Administrators | 1 | 2021 | 2 | 0.210 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2013 | 1534 | 0.210 |
Why?
|
| Prevalence | 2 | 2021 | 1425 | 0.200 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2021 | 3 | 0.200 |
Why?
|
| Burnout, Professional | 1 | 2021 | 17 | 0.200 |
Why?
|
| Adrenalectomy | 1 | 2020 | 24 | 0.200 |
Why?
|
| Risk Factors | 3 | 2021 | 3414 | 0.190 |
Why?
|
| Glucose Tolerance Test | 2 | 2012 | 66 | 0.190 |
Why?
|
| Buffers | 1 | 2020 | 16 | 0.190 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2006 | 162 | 0.190 |
Why?
|
| Regression Analysis | 1 | 2021 | 429 | 0.190 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 228 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2005 | 756 | 0.180 |
Why?
|
| Cytokines | 1 | 2023 | 569 | 0.180 |
Why?
|
| Dietary Fats | 2 | 2011 | 115 | 0.180 |
Why?
|
| Cells, Cultured | 4 | 2008 | 1442 | 0.180 |
Why?
|
| Inhalation Exposure | 1 | 2019 | 37 | 0.180 |
Why?
|
| Sexuality | 2 | 2014 | 50 | 0.170 |
Why?
|
| Arginine Vasopressin | 2 | 2012 | 13 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 137 | 0.170 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2020 | 155 | 0.170 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 109 | 0.170 |
Why?
|
| Heart | 1 | 2020 | 178 | 0.170 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 51 | 0.170 |
Why?
|
| Kidney | 1 | 2021 | 322 | 0.170 |
Why?
|
| Apolipoproteins E | 1 | 2019 | 129 | 0.170 |
Why?
|
| Phosphorylation | 3 | 2021 | 878 | 0.160 |
Why?
|
| Myocardium | 1 | 2020 | 224 | 0.160 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 165 | 0.160 |
Why?
|
| Obesity, Abdominal | 1 | 2018 | 26 | 0.160 |
Why?
|
| Analysis of Variance | 3 | 2019 | 528 | 0.160 |
Why?
|
| Immunohistochemistry | 5 | 2019 | 859 | 0.160 |
Why?
|
| Fatty Acids, Nonesterified | 4 | 2020 | 39 | 0.150 |
Why?
|
| Benzamides | 1 | 2018 | 76 | 0.150 |
Why?
|
| Blood Pressure | 1 | 2021 | 613 | 0.150 |
Why?
|
| Depression | 1 | 2023 | 664 | 0.150 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 416 | 0.150 |
Why?
|
| Naltrexone | 2 | 2013 | 30 | 0.150 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 2 | 2006 | 25 | 0.140 |
Why?
|
| Triglycerides | 2 | 2014 | 129 | 0.140 |
Why?
|
| Medical Records | 1 | 2015 | 37 | 0.140 |
Why?
|
| Child | 2 | 2021 | 2875 | 0.130 |
Why?
|
| Urban Health Services | 1 | 2015 | 35 | 0.130 |
Why?
|
| Ambulatory Care Facilities | 1 | 2015 | 61 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 217 | 0.130 |
Why?
|
| Mutation | 1 | 2019 | 1023 | 0.130 |
Why?
|
| Hysterectomy | 1 | 2014 | 29 | 0.120 |
Why?
|
| Los Angeles | 1 | 2015 | 368 | 0.120 |
Why?
|
| Anorexia | 1 | 2013 | 4 | 0.120 |
Why?
|
| KATP Channels | 1 | 2013 | 11 | 0.120 |
Why?
|
| Drug Implants | 1 | 2013 | 19 | 0.120 |
Why?
|
| Recombinant Proteins | 3 | 2004 | 485 | 0.120 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 34 | 0.120 |
Why?
|
| Pain Threshold | 1 | 2013 | 24 | 0.120 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2014 | 60 | 0.120 |
Why?
|
| Gene Expression | 2 | 2008 | 639 | 0.120 |
Why?
|
| Glucose | 2 | 2005 | 217 | 0.120 |
Why?
|
| Antiporters | 1 | 2013 | 8 | 0.120 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2013 | 15 | 0.120 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2013 | 58 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2013 | 80 | 0.110 |
Why?
|
| Energy Intake | 2 | 2011 | 160 | 0.110 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 26 | 0.110 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2010 | 9 | 0.110 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 391 | 0.110 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2013 | 103 | 0.110 |
Why?
|
| Calcium | 2 | 2007 | 445 | 0.110 |
Why?
|
| Receptors, Opioid, mu | 1 | 2012 | 47 | 0.110 |
Why?
|
| Double-Blind Method | 1 | 2012 | 269 | 0.110 |
Why?
|
| Endoplasmic Reticulum | 1 | 2012 | 101 | 0.110 |
Why?
|
| Pyrrolidines | 1 | 2012 | 26 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2012 | 298 | 0.100 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2012 | 47 | 0.100 |
Why?
|
| Pyrroles | 1 | 2012 | 54 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2012 | 137 | 0.100 |
Why?
|
| United States | 1 | 2021 | 3894 | 0.100 |
Why?
|
| Time Factors | 2 | 2013 | 1681 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2012 | 112 | 0.100 |
Why?
|
| Analgesia | 1 | 2010 | 20 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2012 | 196 | 0.100 |
Why?
|
| Opioid Peptides | 1 | 2010 | 28 | 0.100 |
Why?
|
| Indoles | 1 | 2012 | 154 | 0.100 |
Why?
|
| Glucagon-Secreting Cells | 1 | 2010 | 1 | 0.100 |
Why?
|
| Aging | 2 | 2013 | 639 | 0.100 |
Why?
|
| Enkephalins | 2 | 2010 | 31 | 0.100 |
Why?
|
| Regeneration | 1 | 2010 | 20 | 0.090 |
Why?
|
| Animals, Newborn | 3 | 2020 | 323 | 0.090 |
Why?
|
| Mitochondria | 1 | 2014 | 454 | 0.090 |
Why?
|
| Insulin-Secreting Cells | 1 | 2010 | 27 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 1426 | 0.090 |
Why?
|
| Cocaine | 1 | 2012 | 219 | 0.090 |
Why?
|
| Models, Biological | 2 | 2016 | 642 | 0.090 |
Why?
|
| Carbenoxolone | 1 | 2008 | 10 | 0.080 |
Why?
|
| Deoxyglucose | 1 | 2008 | 19 | 0.080 |
Why?
|
| Immunoblotting | 1 | 2008 | 170 | 0.080 |
Why?
|
| Aged | 4 | 2013 | 6448 | 0.080 |
Why?
|
| Parathyroidectomy | 1 | 2007 | 2 | 0.080 |
Why?
|
| Thyroidectomy | 1 | 2007 | 6 | 0.080 |
Why?
|
| Hypercalcemia | 1 | 2007 | 12 | 0.080 |
Why?
|
| Cell Line | 3 | 2013 | 1289 | 0.080 |
Why?
|
| Parathyroid Hormone | 1 | 2007 | 36 | 0.080 |
Why?
|
| Thyroxine | 2 | 2004 | 17 | 0.080 |
Why?
|
| Opioid-Related Disorders | 1 | 2009 | 112 | 0.080 |
Why?
|
| Creatinine | 1 | 2007 | 101 | 0.080 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2020 | 143 | 0.080 |
Why?
|
| Serum Albumin | 1 | 2007 | 49 | 0.080 |
Why?
|
| Hypothalamus | 2 | 2005 | 122 | 0.080 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2006 | 23 | 0.070 |
Why?
|
| Homeostasis | 1 | 2008 | 172 | 0.070 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2006 | 2 | 0.070 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (ATP) | 1 | 2006 | 2 | 0.070 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2006 | 6 | 0.070 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2006 | 14 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2006 | 197 | 0.070 |
Why?
|
| Drug Tolerance | 1 | 2006 | 38 | 0.070 |
Why?
|
| Adipocytes | 2 | 2018 | 54 | 0.070 |
Why?
|
| Thyroid Hormones | 1 | 2006 | 26 | 0.070 |
Why?
|
| Spatial Behavior | 1 | 2006 | 22 | 0.070 |
Why?
|
| Glucagon | 1 | 2005 | 7 | 0.070 |
Why?
|
| Islets of Langerhans | 1 | 2005 | 9 | 0.070 |
Why?
|
| Neurophysins | 1 | 2005 | 1 | 0.070 |
Why?
|
| Choice Behavior | 1 | 2006 | 75 | 0.070 |
Why?
|
| Locomotion | 1 | 2006 | 91 | 0.070 |
Why?
|
| Retinoid X Receptor beta | 1 | 2005 | 1 | 0.070 |
Why?
|
| Thyroid Hormone Receptors alpha | 1 | 2005 | 3 | 0.070 |
Why?
|
| Oxytocin | 1 | 2005 | 24 | 0.070 |
Why?
|
| Mifepristone | 1 | 2005 | 33 | 0.060 |
Why?
|
| Luciferases | 1 | 2005 | 62 | 0.060 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 52 | 0.060 |
Why?
|
| Response Elements | 1 | 2005 | 52 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1056 | 0.060 |
Why?
|
| Mutagenesis | 1 | 2005 | 87 | 0.060 |
Why?
|
| Cheek | 1 | 2004 | 14 | 0.060 |
Why?
|
| Tretinoin | 1 | 2005 | 50 | 0.060 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2004 | 6 | 0.060 |
Why?
|
| Prolactin | 1 | 2004 | 59 | 0.060 |
Why?
|
| Pregnancy | 3 | 2020 | 1503 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 608 | 0.060 |
Why?
|
| Radiography | 1 | 2004 | 75 | 0.060 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 255 | 0.060 |
Why?
|
| Withholding Treatment | 1 | 2004 | 29 | 0.060 |
Why?
|
| Hydroxysteroid Dehydrogenases | 1 | 2003 | 1 | 0.060 |
Why?
|
| Self Administration | 2 | 2013 | 41 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2007 | 1349 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2006 | 469 | 0.060 |
Why?
|
| Rats, Wistar | 2 | 2013 | 202 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2003 | 139 | 0.060 |
Why?
|
| Cerebral Cortex | 1 | 2005 | 274 | 0.060 |
Why?
|
| RNA Interference | 2 | 2014 | 225 | 0.060 |
Why?
|
| Musculoskeletal Physiological Phenomena | 1 | 2002 | 1 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2004 | 182 | 0.060 |
Why?
|
| Trypanosoma cruzi | 1 | 2004 | 144 | 0.050 |
Why?
|
| Neurons | 2 | 2006 | 1130 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 550 | 0.050 |
Why?
|
| Muscle, Skeletal | 2 | 2014 | 257 | 0.050 |
Why?
|
| Bone Density | 1 | 2002 | 76 | 0.050 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2021 | 11 | 0.050 |
Why?
|
| Hippocampus | 1 | 2005 | 546 | 0.050 |
Why?
|
| Mecamylamine | 1 | 2020 | 14 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 233 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2020 | 114 | 0.050 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2020 | 30 | 0.050 |
Why?
|
| Spironolactone | 1 | 2021 | 36 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 468 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2020 | 93 | 0.050 |
Why?
|
| Imidazoles | 1 | 2020 | 124 | 0.050 |
Why?
|
| Pyridines | 1 | 2020 | 113 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 74 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2021 | 356 | 0.050 |
Why?
|
| Echocardiography | 1 | 2020 | 144 | 0.050 |
Why?
|
| Heart Ventricles | 1 | 2020 | 121 | 0.040 |
Why?
|
| Public Health | 1 | 2023 | 348 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 245 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 60 | 0.040 |
Why?
|
| Cognition | 1 | 2002 | 373 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 139 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2021 | 283 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 490 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 459 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 2016 | 34 | 0.040 |
Why?
|
| Sirtuin 1 | 1 | 2016 | 32 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2019 | 834 | 0.040 |
Why?
|
| Caspases | 1 | 2016 | 132 | 0.040 |
Why?
|
| Inflammation | 1 | 2020 | 577 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1149 | 0.030 |
Why?
|
| 3T3-L1 Cells | 1 | 2014 | 14 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2014 | 26 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2014 | 104 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 2128 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2014 | 8 | 0.030 |
Why?
|
| Reinforcement Schedule | 1 | 2013 | 13 | 0.030 |
Why?
|
| Pyrazines | 1 | 2014 | 23 | 0.030 |
Why?
|
| Arousal | 1 | 2014 | 82 | 0.030 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2013 | 21 | 0.030 |
Why?
|
| Pedigree | 1 | 2013 | 64 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 48 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 89 | 0.030 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2013 | 45 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 122 | 0.030 |
Why?
|
| Gluconeogenesis | 1 | 2013 | 10 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2013 | 38 | 0.030 |
Why?
|
| Nucleus Accumbens | 1 | 2013 | 80 | 0.030 |
Why?
|
| Extinction, Psychological | 1 | 2013 | 89 | 0.030 |
Why?
|
| Dopamine | 1 | 2013 | 232 | 0.030 |
Why?
|
| Dynorphins | 1 | 2010 | 14 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 420 | 0.020 |
Why?
|
| Naloxone | 1 | 2010 | 50 | 0.020 |
Why?
|
| Nociceptors | 1 | 2010 | 31 | 0.020 |
Why?
|
| Swimming | 1 | 2010 | 37 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 43 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2010 | 120 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 131 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2010 | 161 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 152 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 1802 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2014 | 587 | 0.020 |
Why?
|
| Hyperthyroidism | 1 | 2006 | 5 | 0.020 |
Why?
|
| Median Eminence | 1 | 2006 | 10 | 0.020 |
Why?
|
| Proglucagon | 1 | 2005 | 1 | 0.020 |
Why?
|
| Tissue Adhesives | 1 | 2004 | 2 | 0.020 |
Why?
|
| Dihydrotestosterone | 1 | 2004 | 26 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 55 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 2004 | 62 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2004 | 58 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 33 | 0.020 |
Why?
|
| Cell Division | 1 | 2005 | 296 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2004 | 41 | 0.020 |
Why?
|
| Proteome | 1 | 2005 | 132 | 0.020 |
Why?
|
| Kinetics | 1 | 2005 | 650 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 605 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2004 | 202 | 0.010 |
Why?
|
| Estradiol | 1 | 2004 | 244 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 1124 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 1490 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2004 | 775 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 375 | 0.010 |
Why?
|